| scholarly article | Q13442814 |
| P2093 | author name string | Bruce Kaplan | |
| Sarah E Yost | |||
| Olivia R Blume | |||
| P2860 | cites work | The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection | Q28299356 |
| Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection | Q33382552 | ||
| Abrogation of anti-HLA antibodies via proteasome inhibition | Q33384617 | ||
| Eculizumab in acute recurrence of thrombotic microangiopathy after renal transplantation | Q33396637 | ||
| The HLA system. First of two parts | Q34023681 | ||
| Complement C4d in graft capillaries -- the missing link in the recognition of humoral alloreactivity | Q35142594 | ||
| Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics | Q35745999 | ||
| Transplant: immunology and treatment of rejection | Q35787476 | ||
| Structurally based epitope analysis of major histocompatibility complex class I-related chain A (MICA) antibody specificity patterns | Q37085307 | ||
| Monitoring and treating posttransplant human leukocyte antigen antibodies | Q37449657 | ||
| Rejection of the kidney allograft | Q37798268 | ||
| Antibody-mediated rejection in kidney transplantation: an update | Q37835834 | ||
| C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival | Q37856004 | ||
| Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. | Q39904553 | ||
| Banff 07 classification of renal allograft pathology: updates and future directions | Q40121163 | ||
| Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection | Q43166691 | ||
| Bortezomib as the sole post-renal transplantation desensitization agent does not decrease donor-specific anti-HLA antibodies | Q43178469 | ||
| Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection | Q43747982 | ||
| High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis | Q43906723 | ||
| Rituximab as treatment for refractory kidney transplant rejection | Q44899030 | ||
| Impact of rituximab therapy for treatment of acute humoral rejection | Q45361905 | ||
| Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation | Q46270876 | ||
| Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production | Q46270888 | ||
| Experience with antibody-mediated rejection in kidney allograft recipients. | Q46683385 | ||
| Histo-blood group type change of the graft from B to O after ABO mismatched heart transplantation | Q47625379 | ||
| Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection | Q47869308 | ||
| Differential effect of pretransplant blood transfusions on immune effector and regulatory compartments in HLA-sensitized and nonsensitized recipients. | Q51026811 | ||
| Histopathology and immunophenotype of the spleen during acute antibody-mediated rejection. | Q51575020 | ||
| Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. | Q51736686 | ||
| Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. | Q54469292 | ||
| Pharmacodynamics of Rituximab in Kidney Transplantation | Q62588639 | ||
| Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation | Q79741109 | ||
| Association between C4d staining in renal transplant biopsies, production of donor-specific HLA antibodies, and graft outcome | Q79820431 | ||
| Rituximab therapy for acute humoral rejection after kidney transplantation | Q80318231 | ||
| Successful therapy with rituximab of refractory acute humoral renal transplant rejection: a case report | Q80664944 | ||
| Protein A immunoadsorption therapy in the highly sensitized kidney transplant candidates | Q83962057 | ||
| Decrease of blood type antigenicity over the long-term after ABO-incompatible kidney transplantation | Q84203120 | ||
| Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation | Q84420087 | ||
| Serum major-histocompatibility-complex class I-related chain A antibody detection for the evaluation of graft dysfunction in renal allograft recipients | Q84967350 | ||
| Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients | Q84977614 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 201754 | |
| P577 | publication date | 2012-03-24 | |
| P1433 | published in | Journal of transplantation | Q26842064 |
| P1476 | title | Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes | |
| P478 | volume | 2012 |
| Q50598673 | A unique case of rituximab-related posterior reversible encephalopathy syndrome in a heart transplant recipient with posttransplant lymphoproliferative disorder. |
| Q60919346 | Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering |
| Q34841849 | Diagnosis and management of antibody-mediated rejection: current status and novel approaches |
| Q49264301 | Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation |
| Q90000829 | Immunoadsorption enables successful rAAV5-mediated repeated hepatic gene delivery in nonhuman primates |
| Q37375622 | Incidence and clinical significance of de novo donor specific antibodies after kidney transplantation |
| Q52310243 | Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies. |
| Q38176005 | Novel immunosuppressive agents in kidney transplantation |
| Q39968188 | Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field |
| Q46592834 | Simultaneous extracorporeal membrane oxygenation and therapeutic plasma exchange procedures are tolerable in both pediatric and adult patients |
| Q38237360 | The Tao of myeloma |
Search more.